Breathing brief, moderate bouts of low oxygen trigger (low oxygen therapy, LOT) spinal plasticity (the ability of the nervous system to strengthen neural pathways based on new experiences), and improve walking after spinal cord injury (SCI). The greatest improvements in walking ability occur when LOT is administered prior to skill-based walking practice (WALK). However, the enduring benefits of LOT on walking recovery may be undermined by the accumulation of LOT-induced increase in extracellular adenosine. The goal of the study is to understand the extent to which istradefylline (adenosine 2a receptor antagonist) may limit the competing mechanisms of adenosine on LOT-induced walking recovery following SCI.

Start Date01 Sep 2024

Sponsor / Collaborator-

CTR20230645 / RecruitingPhase 3

伊曲茶碱片用于改善左旋多巴治疗原发性帕金森病剂末现象的多中心、随机、双盲、安慰剂平行对照临床试验

[Translation] A multicenter, randomized, double-blind, placebo-controlled clinical trial of istradefylline tablets for improving the wearing-off phenomenon of levodopa in the treatment of primary Parkinson's disease

评价伊曲茶碱片用于改善左旋多巴治疗原发性帕金森病剂末现象的有效性和安全性

[Translation]

To evaluate the efficacy and safety of istradefylline tablets in improving the wearing-off phenomenon of levodopa in the treatment of primary Parkinson's disease

Start Date21 Jun 2023

Sponsor / Collaborator

Shandong Chuangxin Pharmaceutical Research & Development Co., Ltd.

NCT05885360 / Active, not recruitingPhase 4IIT

Istradefylline Effect on Parkinson's Disease Tremor, Motor Symptoms and Non-motor Symptoms

This is an investigator-initiated trial. In this 6-month open label, single arm, exploratory pilot study, the investigator intends to enroll a pilot sample of 25 patients with Parkinson's disease who are being started on the novel FDA approved medication "Istradefylline'' as an add on therapy for management of their motor symptoms (based on the judgment of the movement disorders specialist, if patients are in sub-optimal management of their symptoms on maximum tolerable dose of their dopaminergic medications). The investigator will evaluate their motor symptoms before starting the new medication, including their MDS-UPDRS total and MDS-UPDRS-III scores.

Start Date20 Jan 2023

Sponsor / Collaborator

Georgetown University

[+1]

100 Clinical Results associated with Istradefylline

100 Translational Medicine associated with Istradefylline

100 Patents (Medical) associated with Istradefylline

287

Literatures (Medical) associated with Istradefylline

01 Mar 2024·eNeurologicalSci

Effect of istradefylline on postural abnormalities in patients with Parkinson's disease: An association study of baseline postural angle measurements with changes in Unified Dystonia Rating Scale total score

Article

Author: Shimokawa, Toshio ; Koh, Jinsoo ; Takeshima, Takao ; Takahashi, Makio ; Ito, Hidefumi ; Yamashita, Hirofumi ; Kajimoto, Yoshinori

In our previous study, istradefylline treatment in patients with Parkinson's disease (PD) improved postural abnormalities (PAs), as seen from a decrease in the mean Unified Dystonia Rating Scale (UDRS) total score from week 0 to week 24. A subgroup analysis based on baseline clinical characteristics investigated the association between improvement in the UDRS total score and istradefylline treatment. However, the association between an objective assessment of PAs and improvement in the UDRS total score is unclear. This ad hoc analysis investigated the association between improvement in the UDRS total score after istradefylline treatment and baseline trunk and neck angles, objective assessments of PAs, measured from patients' photographs taken in the previous study. The patients (n = 31) were stratified into groups based on the trunk forward flexion angle (TFFA), trunk lateral flexion angle (TLFA), and neck flexion angle (NFA) values at baseline. From week 0 to week 24, significant improvements in the UDRS total score were found in median percent change (-8.33% [interquartile range: -43.97, 0.00], P = 0.039) in patients with equal to or above the median TFFA values, and in median change (-‍1.50 [-9.25, 0.00], P = 0.015) and median percent change (-13.33% [-50.47, 0.00], P = 0.009) in patients with equal to or above the median TLFA values. Patients with more advanced PAs showed more consistent improvements in the UDRS total score with istradefylline. Baseline TFFA and TLFA values, which are objective values, may be useful to assess the istradefylline effectiveness in patients with PD and PAs.

01 Dec 2023·The mental health clinician

Management of OFF condition in Parkinson disease

Article

Author: Koch, Jessa

Abstract:

Parkinson disease (PD) impacts nearly 1 million individuals in the United States. Nearly every patient with PD will require therapy with dopamine in the form of levodopa as the disease progresses. In more advanced stages of the disease, patients will experience motor fluctuations and require adjustment to their medication regimens to maintain good control of their symptoms. During the last 10 years, several new therapeutic treatment options have come to the market to treat motor fluctuations and improve patient quality of life. Some of these agents represent additional options to previously available drug classes, such as the catechol-O-methyl transferase (COMT) inhibitor, opicapone, and monoamine-oxidase B-inhibitor (MAO-B inhibitor), safinamide, as well as new dosage forms for available therapeutics. One new agent, istradefylline, has a novel mechanism in the treatment of PD. The place in therapy for these newer therapeutic options will be explored through a series of patient cases. This article focuses on evidence-based recommendations for the use of these newer options in the management of patients experiencing OFF episodes.

01 Mar 2024·Neuroscience letters

Adenosine A2A receptor antagonist KW6002 protects against A53T mutant alpha-synuclein-induced brain damage and neuronal apoptosis in Parkinson's disease mice by restoring autophagic flux

Article

Author: Yuan, Jianshu ; Xu, Lingli ; Wang, Yuwen ; Liu, Xiaotian ; Hu, Qidi

BACKGROUND:

Protein misfolding and inclusion body aggregation caused by α-Syn mutations in the brain often cause neurodegeneration and cognitive impairment, among which the A53T point mutation is more common. Inhibition of adenosine A2A receptor (A_2AR) can alleviate the pathological symptoms of brain dysfunction caused by A53T-α-Syn protofibrils, but the mechanism of action is still unclear.

AIM:

This studies aimed to investigate the potential therapeutic role of the A_2AR inhibitor KW6002 in a mouse model of brain synucleinopathy.

METHODS:

A53T-α-Syn fibre precursor cell nuclear protein was injected into the bilateral prefrontal cortex of mice to establish a synucleinopathy animal model, and the A_2AR inhibitor KW6002 (5 mg/kg) was injected intraperitoneally to intervene.

RESULT:

The intracerebral injection of A53T-α-Syn protofibrils triggers the formation of inclusion bodies in the brain, leading to astrocyte activation, an increased number of apoptotic cells, and suppression of autophagic flux. The administration of KW6002 significantly reversed these phenomena. In vitro experiments revealed that A53T-α-Syn protofibrils inhibited HT-22 autophagy in mouse hippocampal neuronal cells, whereas KW6002 increased cellular autophagic flux, upregulated the expression of LAMP2A and Hsc70 proteins and inhibited the expression of SQSTM1 protein. The present study suggests that KW6002 reduces the level of α-Syn phosphorylation by inhibiting A_2AR protein, at the same time, enhances the autophagic flux of neuronal cells, resulting in the degradation of A53T-α-Syn protofibrils and thus reducing the neuronal toxicity and apoptosis induced by A53T-α-Syn protofibrils.

CONCLUSION:

KW6002 has a significant protective effect on neuronal injury induced by A53T-α-Syn.

News (Medical) associated with Istradefylline

12 Apr 2024

·www.prnewswire.com

Kyowa Kirin to Present a Safety Meta-Analysis of NOURIANZ® (istradefylline) and Other Parkinson's Disease Add-On Therapies

Findings to be presented at 2024 American Academy of Neurology annual conference between April 13-18 in Denver, CO PRINCETON, N.J., April 12, 2024 /PRNewswire/ -- Kyowa Kirin, Inc., an affiliate of Kyowa Kirin Co., Ltd. (Kyowa Kirin, TSE: 4151), a global specialty pharmaceutical company based in Japan, will announce findings from an updated systematic literature review (SLR) and meta-analysis comparing the safety of NOURIANZ® (istradefylline) in relation to other levodopa adjunctive therapies for patients with Parkinson's Disease (PD).1,2 NOURIANZ is an adenosine receptor antagonist used with levodopa/carbidopa to treat adults with PD experiencing "off" episodes, the return of Parkinson's symptoms between medication doses. The findings will be presented at the American Academy of Neurology (AAN) 2024 Annual Meeting, during a poster presentation on Monday, April 15, from 5:30 – 6:30 PM MDT. Parkinson's disease is a progressive, neurodegenerative disease characterized by motor symptoms such as tremors, rigidity, slow movement, and postural instability. Within 5 years of starting levodopa/carbidopa treatment, half of people living with PD begin to experience "off" time, including problems with movement.3 Adjunctive therapies may be used to treat these episodes but are often hampered by safety and tolerability issues that limit their clinical utility.1 "With the growing landscape of adjunctive therapies for Parkinson's disease, it is important for physicians to have data that demonstrates the relative risk profiles of these treatment options," said lead author Yasar Torres-Yaghi, MD, MedStar Georgetown University Hospital. "These data provide useful information on safety and tolerability of these therapies, an important factor for physicians when choosing an appropriate adjunctive therapy for patients experiencing "off" episodes." About the Study Researchers updated a previously published SLR with an additional 20 randomized controlled trials from Jan 1, 2010, to April 15, 2019, evaluating adjunctive therapies in patients with PD. The study analyzed data from a total of 57 randomized clinical trials involving 11,517 patients. Interventions included COMT inhibitors, monoamine oxidase type B (MAO-B) inhibitors, dopamine agonists (DAs), istradefylline, and amantadine ER. A pair-wise meta-analysis was conducted to calculate summary odds ratios (OR) and 95% confidence intervals (CI). Bucher indirect comparisons were used to generate estimates of relative safety, and information on study design, eligibility criteria, and baseline characteristics were extracted for heterogeneity assessment. About NOURIANZ® NOURIANZ is an adenosine receptor antagonist indicated as an adjunctive treatment to levodopa/carbidopa in adult patients with Parkinson's disease (PD) experiencing "off" episodes. It is not known if istradefylline is safe and effective in children.4 Important Safety Information Warnings and Precautions Dyskinesia: NOURIANZ in combination with levodopa may cause dyskinesia or exacerbate pre-existing dyskinesia. In clinical trials, 1% of patients treated with either NOURIANZ 20 mg or 40 mg discontinued treatment because of dyskinesia, compared to 0% for placebo. Hallucinations / Psychotic Behavior: Because of the potential risk of exacerbating psychosis, patients with a major psychotic disorder should not be treated with NOURIANZ. Consider dosage reduction or discontinuation if a patient develops hallucinations or psychotic behaviors while taking NOURIANZ. Impulse Control / Compulsive Behaviors: Patients treated with NOURIANZ and one or more medication(s) for the treatment of Parkinson's disease (including levodopa) may experience intense urges to gamble, increased sexual urges, intense urges to spend money, binge or compulsive eating, and/or other intense urges, and the inability to control these urges. In clinical trials, 1 patient treated with NOURIANZ 40 mg was reported to have impulse control disorder, compared to no patient on NOURIANZ 20 mg or placebo. DRUG INTERACTIONS The maximum recommended dosage in patients taking strong CYP3A4 inhibitors is 20 mg once daily. Avoid use of NOURIANZ with strong CYP3A4 inducers. SPECIAL POPULATIONS Pregnancy: Based on animal data, may cause fetal harm. ADVERSE REACTIONS The most common adverse reactions with an incidence ≥5% and occurring more frequently than with placebo were dyskinesia (15%, 17%, and 8%), dizziness (3%, 6%, and 4%), constipation (5%, 6%, and 3%), nausea (4%, 6%, and 5%), hallucination (2%, 6%, and 3%), and insomnia (1%, 6%, and 4%) for NOURIANZ 20 mg, 40 mg, and placebo, respectively. You are encouraged to report suspected adverse reactions to Kyowa Kirin, Inc. at 1-844-768-3544 or FDA at 1-800-FDA-1088 or . Please click to see full Prescribing Information for Nourianz. About Kyowa Kirin Kyowa Kirin aims to discover and deliver novel treatments with life-changing value. As a Japan-based Global Specialty Pharmaceutical Company, we have invested in drug discovery and biotechnology innovation for more than 70 years and are currently working to engineer the next generation of antibodies and cell and gene therapies with the potential to help patients with high unmet medical needs, focusing on bone/mineral, intractable hematological diseases/hemato oncology, and rare diseases. A shared commitment to our values, to sustainable growth, and to making people smile unites us across the globe. You can learn more about the business of Kyowa Kirin at: kkna.kyowakirin.com References Torres-Yaghi Y., Qian, J. et al. (2024). Comparative Safety of Istradefylline Among Parkinson's Disease Adjunctive Therapies: A Systematic Review and Meta-Analysis of Randomized Controlled Studies. Data presented at the 2024 American Academy of Neurology Annual Meeting, April 13-18, 2024, Denver, CO. Stowe R et al. Movement disorders. 2011;26(4):587-98 Hickey, P., & Stacy, M. (2011). Available and Emerging Treatments for Parkinson's Disease: A Review. Drug Design, Development and Therapy, 5, 241-254. doi:10.2147/DDDT.S11836 NOURIANZ. Prescribing Information. Kyowa Kirin Inc. Princeton, NJ. SOURCE Kyowa Kirin

Clinical ResultClinical Study

09 Jan 2024

·www.biospace.com

Marvel Biosciences to Collaborate with Tau Expert Dr. Emmanuel Planel

Calgary, Alberta--(News - January 8, 2024) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a collaboration with Professor Emmanuel Planel of Laval University to study the acute effect of MB-204 on Tau protein phosphorylation in mice. Abnormal tau phosphorylation is a hallmark of neurodegenerative diseases such as Alzheimer's disease. "We are very pleased to have the opportunity to collaborate with Dr. Planel, a world leader on Tau pathogenesis," commented Dr. Mark Williams, CSO of Marvel. "The A2a receptor, the target of MB-204, has repeatedly been shown to modulate Tau phosphorylation in multiple disease models. When Tau is hyperphosphorylated, it becomes more prone to clumping, similar to beta amyloid. We intend to test the effect of MB-204 on rapidly reducing Tau phosphorylation in mice using a simple technique pioneered by Dr. Planel." "I am pleased to be working with Marvel on testing their A2a antagonist in our acute mouse model of Tau hyperphosphorylation," noted Dr. Planel. "The pathways affected by the A2a receptor seem to be a very reasonable approach to reducing Tau phosphorylation and we look forward to testing MB-204 in our model." "With the approvals of beta amyloid targeted treatments such as lecanemab and aducanumab for Alzheimer's Disease, more attention is turning to Tau," said Rod Matheson, CEO of Marvel. "MB-204 has completed its pre-clinical 4-week GLP toxicology studies and cGMP manufacturing and is Phase 1 clinical trial ready. We will continue to update the market on our progress with our pre-clinical and clinical programs." MB-204 is a novel fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline which has completed cGMP manufacturing and 4-week GLP toxicology studies. About Marvel Biosciences Corp. Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies. Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, Autism and ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline. Contact Information Marvel Biosciences Corp. J. Roderick (Rod) Matheson, Chief Executive Officer or Dr. Mark Williams, President and Chief Science Officer Tel: 403 770 2469 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party. This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations. To view the source version of this press release, please visit

Phase 1

16 Nov 2023

·www.biospace.com

Marvel Biosciences Invited to Test MB-204 on Autism by French University

Calgary, Alberta--(News - November 16, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce a collaboration with Dr. Julie Le Merrer and Dr. Jerome Becker at iBrain Institute, Tours, France to study the effects of MB-204 in mouse models of autism. "We are very pleased to have the opportunity to collaborate with Dr. Le Merrer and Dr. Becker who have identified a new pathway to potentially treat autism," commented Dr. Williams, CSO of Marvel. "Normally, we would observe that social interaction is a rewarding experience but in autism this does not appear be the case. Drs. Le Merrer and Becker have shown that mice can be treated with drugs like MB-204 which, remarkably, almost completely reverses asocial behaviour in multiple mouse models of autism. Autism affects nearly 1 in 36 children and there are few effective known treatments, so this is very exciting." "We believe that in autism, there is a common problem with the dopamine D2 reward circuitry signaling in the Nucleus accumbens which can be restored by inhibiting the A2a receptor," said Dr. Becker, who published their findings in the May 2023 issue of Biological Psychiatry. "Having seen some of the pre-clinical data on MB-204, which targets the A2a receptor, we are keen to test effects of the molecule in pre-clinical models of autism in our laboratory." "There is also an intriguing overlap in symptoms between autism and especially late-stage Alzheimer's disease," explained Rod Matheson, CEO of Marvel. "Specifically with respect to social withdrawal and loss of verbal communication, MB-204 could represent a truly valuable new approach to treat both of these diseases and depression." MB-204 is a novel fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline which has completed cGMP manufacturing and 4-week GLP toxicology studies. About Marvel Biosciences Corp. Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies. Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline. Contact Information Marvel Biosciences Corp. J. Roderick (Rod) Matheson, Chief Executive Officer or Dr. Mark Williams, President and Chief Science Officer Tel: 403 770 2469 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release. All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party. This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law. To view the source version of this press release, please visit

Drug Approval

100 Deals associated with Istradefylline

External Link

KEGG	Wiki	ATC	Drug Bank
D04641	Istradefylline	N04B	DB11757

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Parkinson Disease	JP	Kyowa Kirin Co., Ltd.	25 Mar 2013

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Primary Parkinson's disease	Phase 3	CN	CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.	28 Feb 2019
Drug abuse	Phase 1	US	Kyowa Kirin Co., Ltd.	01 Jan 2016
Liver Diseases	Phase 1	US	Kyowa Kirin Co., Ltd.	01 Aug 2014

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


MDS2023	Not Applicable	Parkinson Disease \| Dystonia	-	Istradefylline	maahjorjhg(jrljboeqlp) = qhvubkcpuq sbadobqopq (dpbxndgcwg )	-	27 Aug 2023
				Istradefylline	maahjorjhg(jrljboeqlp) = qscuhleijl sbadobqopq (dpbxndgcwg )
ISTRA ADJUST PD (MDS2022)	Not Applicable	Parkinson Disease	114	Istradefylline	rwspiunkfr(dhzjbulgkv) = jyifhputsk xiwtomdies (qqktpkmdhh )	-	15 Sep 2022
				Control (no Istradefylline)	rwspiunkfr(dhzjbulgkv) = cysbktofim xiwtomdies (qqktpkmdhh )
MDS2021	Not Applicable	Parkinson Disease fasting glucose \| HbA1c \| insulin ... View more	-	IST-LD combination group	pgcoizlzwe(fmvlkymdtq) = cwujfobbxp grbhdtbifu (tdtpunezhr ) View more	-	17 Sep 2021
				LD group	pgcoizlzwe(fmvlkymdtq) = ocymklmztq grbhdtbifu (tdtpunezhr ) View more
NCT01968031 (CTgov)	Phase 3	Parkinson Disease	613	Placebo (Placebo)	dqlwpohlmk(icwadxjgjs) = tcgwuoozhs uttxrcuulf (wiwdhbapxb, lnytrriylw - ydecdmvzyl) View more	-	20 Nov 2020
				Placebo+Istradefylline 20 mg (Istradefylline 20 mg/Day)	dqlwpohlmk(icwadxjgjs) = gvybuwdvig uttxrcuulf (wiwdhbapxb, qtfevyszur - kvgwpjtsnc) View more
pooled analysis of four pivotal randomized controlled trials of istradefylline (ANA2020)	Phase 3	-	1,143	Istradefylline 20mg/day	xnkhmksjqn(cysplpzosw) = saflgncbke ssgsdrjvkx (yttcnbbsck, -1.10 to -0.40) View more	Positive	25 Sep 2020
				Istradefylline 40mg/day	xnkhmksjqn(cysplpzosw) = qahdlizrvd ssgsdrjvkx (yttcnbbsck, -1.17 to -0.47) View more
ANA2020	Phase 2/3	-	1,160	Istradefylline 20 mg/day	laaxmzphoj(coetxmhkni) = The most common TEAE was dyskinesia (20 mg/day, 14.6%; 40 mg/day, 16.7%; placebo, 7.5%) ryfhtdvyhi (rrwxvfrqev ) View more	Positive	25 Sep 2020
				Istradefylline 40 mg/day
MDS2020	Not Applicable	-	31	Istradefylline 20 mg/day	yftutuqhxq(pwwlupxcnc) = 2 (6.5%) patients bjxlhcluuu (nnxcsfwwwe ) View more	-	12 Sep 2020
				Placebo
MDS2020	Phase 2/3	Parkinson Disease	1,143	Istradefylline 20mg/day	girmqqppww(zjrvqlpewj) = Dyskinesia was the most frequent adverse event (20mg, 15%; 40mg, 17%; placebo, 8%) pccfmrlybs (jfgdhwonom )	Positive	12 Sep 2020
MDS2020	Not Applicable	Parkinson Disease hexokinase (HK-1) \| HK-2 \| insulin-like growth factor type 1 (IGF-1)	-	L-DOPA/IST combination therapy	fitfoemlaf(ahuketzidv) = depression 6.3 % xedfocotdv (ejmcqpwjvi ) View more	-	12 Sep 2020
MDS2019	Not Applicable	Parkinson Disease	-	Istradefylline	dmyvtvcieu(qwsxepjpok) = dyskinesia was the most frequent reported AE ymfhjwvuui (snhurvrkit )	Positive	22 Sep 2019
				Placebo

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis